N

    Nurix Therapeutics Inc (NRIX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $25.78
    -0.43 (-1.64%)

    Market Cap: $2.68B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    46%(11/24)
    Avg Surprise
    -4.95%

    Upcoming Estimates

    Period ending Aug 31, 2026
    EPS Consensus$5.11
    Range$4.29 - $5.74
    3 analysts
    EPS RevisionsNo revisions (7d)
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.74-114.4%
    60d ago$-0.74-114.4%
    30d ago$-0.61-112.0%
    7d ago$5.11+0.0%
    Current$5.11
    Revenue Consensus
    $480M
    Range$25M - $714M
    3 analysts
    Period ending Nov 30, 2026
    EPS Consensus$-1.85
    Range$-6.61 - $0.19
    4 analysts
    Revenue Consensus
    $246M
    Range$227M - $281M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Nov 26EST
    		-$-1.85---
    Aug 26EST
    		-$5.11---
    May 26
    Reported Jul 9
    		$-0.81$-0.73-10.96%Miss-55.8%
    Feb 26
    Reported Apr 8
    		$-0.79$-0.83+4.76%Beat-17.9%
    Nov 25
    Reported Jan 28
    		$-0.82$-0.92+10.87%Beat-9.3%
    Aug 25
    Reported Oct 9
    		$-1.03$-0.85-21.18%Miss-53.7%
    May 25
    Reported Jul 9
    		$-0.52$-0.74+29.73%Beat+26.8%
    Feb 25
    Reported Apr 8
    		$-0.67$-0.76+11.84%Beat+11.8%
    Nov 24
    Reported Jan 28
    		$-0.75$-0.67-12.12%Miss+2.6%
    Aug 24
    Reported Oct 11
    		$-0.67$-0.68+1.47%Beat+1.5%
    May 24
    Reported Jul 11
    		$-0.71$-0.63-12.70%Miss-57.8%
    Feb 24
    Reported Apr 10
    		$-0.76$-0.80+5.00%Beat-1.3%
    Nov 23
    Reported Feb 15
    		$-0.77$-0.50-54.00%Miss+11.5%
    Aug 23
    Reported Oct 12
    		$-0.68$-0.74+8.11%Beat+24.4%
    May 23
    Reported Jul 13
    		$-0.45$-0.57+21.05%Beat+55.4%
    Feb 23
    Reported Apr 13
    		$-0.75$-0.87+13.79%Beat+21.1%
    Nov 22
    Reported Feb 9
    		$-0.87$-0.79-10.13%Miss-2.4%
    Aug 22
    Reported Oct 6
    		$-0.90$-0.95+5.26%Beat-38.5%
    May 22
    Reported Jul 7
    		$-1.01$-0.99-2.02%Miss-68.3%
    Feb 22
    Reported Apr 7
    		$-0.95$-0.89-6.74%Miss-50.8%
    Nov 21
    Reported Jan 27
    		$-0.85$-0.69-23.19%Miss-66.7%
    Aug 21
    Reported Oct 14
    		$-0.65$-0.62-4.84%Miss-10.2%
    May 21
    Reported Jul 13
    		$-0.60$-0.56-7.14%Miss+45.0%
    Feb 21
    Reported Apr 13
    		$-0.63$-0.45-40.00%Miss+67.0%
    Nov 20
    Reported Feb 16
    		$-0.51$-0.54+5.56%Beat-
    Aug 20
    Reported Oct 14
    		$-0.59$-0.45-31.11%Miss-
    May 20
    Reported Jul 24
    		$-1.09N/AN/ABeat-
    Feb 20
    Reported May 5
    		$-1.91$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-7.47EV/EBITDA-3.35x
    Price/FCF-9.40xFCF Yield-10.63%
    Profitability
    Profit Margin0.00%Operating Margin-1042.00%
    ROE-80.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio6.34xQuick Ratio6.34x
    Trading Statistics
    Beta1.79Avg Volume1.08M
    52-Week High$28.2352-Week Low$8.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$26.73
    SMA 20$26.39
    SMA 50$24.40
    SMA 200$18.64
    EMA 10$26.45
    EMA 20$26.06
    EMA 50$24.11
    EMA 200$19.06

    MACD

    Line: 0.72Signal: 0.98Hist: -0.25

    ADX

    ADX: 31.1+DI: 23.5-DI: 18.7

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down4.0
    PSAR$27.74

    Bollinger Bands

    Upper Band$28.02
    Lower Band$24.75
    %B Position1238%(Upper)
    Band Width0.31

    RSI (14-Day)

    Neutral
    51.3

    Momentum Oscillators

    Stoch %K34.4
    Stoch %D46.0
    Williams %R-80.1
    ROC (10d)-5.1%
    Momentum-1.39
    CCI (20d)-55.3
    MFI (14d)51.6

    Volatility Measures

    ATR (14d)$1.01(3.9%)
    StdDev (20d)0.82
    Hist Vol34.8%(Moderate)

    Volume Flow

    VWAP$25.73
    OBV52.7M
    AD Line-37.4M
    CMF (20d)0.209

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio1.0x
    VWMA (20d)$26.47

    Pivot Points

    R3$27.42
    R2$27.15
    R1$26.68
    Pivot Point$26.40
    S1$25.93
    S2$25.66
    S3$25.19

    Advanced Oscillators

    TSI24.47
    Ultimate Osc47.8
    KST115.18

    Financial Data

    QuarterMay 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023Aug 2023
    Total Revenue$9.04M$6.25M$13.58M$7.89M$44.06M$18.45M$13.28M$12.59M$12.09M$16.59M$15.16M$18.47M
    Cost of Revenue$0$0$4.63M$0$0$0$67.22M$0$0$0$49.71M$0
    Gross Profit$9.04M$6.25M$13.58M$7.89M$44.06M$18.45M$13.28M$12.59M$12.09M$16.59M$15.16M$18.47M
    Operating Expenses$103.25M$98.75M$96.67M$99.28M$92.38M$81.32M$77.94M$67.20M$60.63M$61.80M$60.49M$58.48M
    R&D$87.65M$84.14M$83.02M$86.12M$78.10M$69.66M$67.22M$55.48M$48.92M$50.01M$49.71M$47.86M
    SG&A$15.59M$14.61M$13.65M$13.16M$14.28M$11.65M$10.72M$11.72M$11.71M$11.80M$10.78M$10.62M
    Operating Income$-94,204,000$-92,495,000$-83,095,000$-91,385,000$-48,322,000$-62,864,000$-64,657,000$-54,611,000$-48,540,000$-45,219,000$-45,334,000$-40,012,000
    Interest Income$4.40M$5.32M$4.87M$4.96M$5.62M$6.51M$6.12M$5.74M$4.08M$3.79M$3.38M$3.03M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-89,806,000$-87,174,000$-78,221,000$-86,421,000$-42,704,000$-56,351,000$-58,541,000$-48,874,000$-44,456,000$-41,428,000$-41,956,000$-36,982,000
    Income Tax Expense$-271,000$0$0$0$760,000$0$8,000$82,000$90,000$90,000$0$0
    Net Income$-89,535,000$-87,174,000$-78,221,000$-86,421,000$-43,464,000$-56,351,000$-58,549,000$-48,956,000$-44,546,000$-41,518,000$-41,956,000$-36,982,000
    EBITDA$-91,911,000$-90,697,000$-80,331,000$-88,582,000$-45,926,000$-62,293,000$-63,847,000$-54,171,000$-46,608,000$-43,261,000$-43,545,000$-38,273,000
    EBIT$-94,204,000$-92,495,000$-83,095,000$-91,385,000$-48,322,000$-62,864,000$-64,657,000$-54,611,000$-48,540,000$-45,219,000$-45,334,000$-40,012,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NRIX

    News

    Nurix Therapeutics to Participate in Upcoming September Investor Conferences

    Nurix Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its participation in four upcoming investor conferences in September 2026. The company management will engage in fireside chats at the Wells Fargo, H.C. Wainwright, Baird, and Morgan Stanley Healthcare Conferences. These sessions will be webcast live and archived on Nurix's investor relations website.

    Yahoo Finance•9/1/26•
    Neutral

    BlackRock Inc. Buys New Position in Nurix Therapeutics, Inc. $NRIX

    BlackRock Inc. has acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX), purchasing 8.77 million shares valued at $212.8 million, representing an 8.45% stake. Despite this significant institutional investment and a "Moderate Buy" consensus rating from analysts, Nurix Therapeutics reported weaker-than-expected quarterly results with an EPS miss and lower revenue. The company remains unprofitable, with analysts projecting a full-year loss, and recent insider selling has also been noted.

    MarketBeat•8/28/26•
    Neutral

    Elmind Capital LP Invests $11.16 Million in Nurix Therapeutics, Inc. $NRIX

    Elmind Capital LP has acquired a new stake of 460,000 shares, valued at approximately $11.16 million, in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, making it their 14th largest holding. Other institutional investors have also adjusted their positions in Nurix Therapeutics. The article also details Nurix Therapeutics' stock performance, recent earnings, analyst ratings, and insider transactions, noting a consensus "Moderate Buy" rating with a target price of $34.21.

    MarketBeat•8/28/26•
    Neutral

    Trails Edge Capital Partners LP Purchases New Holdings in Nurix Therapeutics, Inc. $NRIX

    Trails Edge Capital Partners LP has acquired a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the second quarter, purchasing over 1.5 million shares valued at approximately $38.1 million, making it their second-largest holding. This comes as other institutional investors have also modified their positions in NRIX, and company insiders have recently sold shares. Nurix Therapeutics stock performance and analyst ratings are also detailed, with a consensus "Moderate Buy" rating.

    MarketBeat•8/28/26•
    Somewhat-Bullish

    313,236 Shares in Nurix Therapeutics, Inc. $NRIX Acquired by ADAR1 Capital Management LLC

    ADAR1 Capital Management LLC has acquired 313,236 shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) worth approximately $7.6 million during the second quarter. Despite missing quarterly earnings and revenue expectations, analysts maintain a "Moderate Buy" rating for NRIX with a consensus price target of $34.21. Insider selling has also occurred, with Gwenn Hansen and Houte Hans Van selling shares.

    MarketBeat•8/26/26•
    Neutral

    Frequently Asked Questions About NRIX

    Does NRIX pay dividends?
    Nurix Therapeutics Inc (NRIX) does not currently pay a regular dividend.
    What is NRIX's market cap?
    Nurix Therapeutics Inc (NRIX) has a market capitalization of $2.68B with a current stock price of $25.78.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In